Clinically Amyopathic Dermatomyositis Associated with Recurrence of Esophageal Cancer: A Case Report

Main Article Content

Anna Eversman
Sayeeda Ahsanuddin
Joel Saltzman
Paula Silverman
Mara Beveridge


clinically amyopathic dermatomyositis, CADM, esophageal adenocarcinoma


Background: Approximately 20% of patients displaying skin changes characteristic of dermatomyositis do not develop clinical or enzymatic evidence of muscle inflammation within 6 months of onset, leading to a diagnosis of clinically amyopathic dermatomyositis (CADM). While the association between dermatomyositis and malignancy is well-documented, the clinical significance of CADM is still being elucidated.

Case Presentation: We report a case of new-onset CADM associated with recurrent esophageal adenocarcinoma for clinical interest and to add to the limited literature on CADM.

Conclusion: To date, there is only one report of concurrent CADM and esophageal cancer. We present this case for clinical interest and to add to the limited literature on CADM.


1) Pinard J, Femia AN, Roman M, et al. Systemic Treatment for Clinically Amyopathic Dermatomyostitis at 4 Tertiary Care Centers. JAMA Dermatol. 2019;155(4):494-496.

2) Sato S, Kuwana M. Clinically amyopathic dermatomyositis. Curr Opin Rheumatol 2010;22:639-43.

3) Lu X, Yang H, Shu X, et al. Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis. PLoS ONE. 2014;9(4):e94128.

4) Goyal S, Nousari HC. Paraneoplastic amyopathic dermatomyositis associated with breast cancer recurrence. J Am Acad Dermatol.1999;(41):874-875.

5) Kikuchi K, Seto Y, Matsubara T, et al. Amyopathic dermatomyositis associated with esophageal cancer. Int J Dermatol. 2008;47:310-311.

6) Gerami P, Schope JM, Mcdonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54(4):597-613.

7) Galimberti F, Li Y, Fernandez AP. Clinically amyopathic dermatomyositis: clinical features, response to medications and malignancy-associated risk factors in a specific tertiary-care-centre cohort. Br J Dermatol. 2016;174(1):158-64.

8) Yu, B. A clinical analysis of cutaneous type dermatomyositis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1994;16:394-396.

9) Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014;343:152-7.

10) Leatham H, Schadt C, Chisolm S, et al. Evidence supports blind screening for internal malignancy in dermatomyositis: Data from 2 large US dermatology cohorts. Medicine (Baltimore). 2018;97(2):e9639.

11) Sontheimer RD. Clinically amyopathic dermatomyositis: what can we now tell our patients? Arch Dermatol. 2010;146(1):76-80.